Omnicell, Inc. (NASDAQ:OMCL) Stock Has Average Price Target of $57.86

Omnicell, Inc. (NASDAQ:OMCL) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $57.86.

A number of research firms recently issued reports on OMCL. Zacks Research upgraded shares of Omnicell from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. Weiss Ratings upgraded Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. KeyCorp restated an “overweight” rating on shares of Omnicell in a research note on Monday, August 24th. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 target price (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Finally, Wells Fargo & Company cut their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st.

Omnicell Stock Down 1.6%

NASDAQ:OMCL traded down $0.56 during trading hours on Friday, reaching $35.39. The company’s stock had a trading volume of 426,747 shares, compared to its average volume of 497,085. The company has a market cap of $1.61 billion, a price-to-earnings ratio of 42.13, a price-to-earnings-growth ratio of 0.90 and a beta of 0.98. Omnicell has a one year low of $29.09 and a one year high of $55.00. The business’s 50-day moving average is $34.56 and its 200-day moving average is $38.48. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%. The business had revenue of $312.21 million for the quarter, compared to the consensus estimate of $310.21 million. During the same period last year, the business earned $0.45 EPS. The firm’s revenue was up 7.4% compared to the same quarter last year. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Equities research analysts predict that Omnicell will post 1.41 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new position in shares of Omnicell in the second quarter valued at approximately $313,044,000. Dimensional Fund Advisors LP increased its position in shares of Omnicell by 6.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock worth $81,791,000 after purchasing an additional 137,834 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in Omnicell by 2.0% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock worth $47,095,000 after buying an additional 27,497 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Omnicell by 31.3% during the 1st quarter. Bank of America Corp DE now owns 580,875 shares of the company’s stock worth $19,390,000 after purchasing an additional 138,537 shares during the last quarter. Finally, First Light Asset Management LLC acquired a new position in Omnicell during the first quarter worth approximately $16,351,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc provides medication-management technology and related services for health care providers. Its solutions are designed to help hospitals, health systems, retail pharmacies and other care settings manage medication inventory, improve workflow efficiency and support medication adherence.

The company’s offerings include automated medication dispensing systems, central pharmacy automation, medication packaging and adherence solutions, pharmacy inventory management tools, and software for medication-use analytics and workflow management.